Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.48 |
| ▸ | GRK6 | P43250 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | CASP3 | P42574 | 3/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450827 | 0.89 | NPSR1 (0.38) | HPGDMEN1KMT2AALOX15ALDH1A1 | |
| SCHEMBL6452047 | 0.88 | NPSR1 (0.41) | HPGDGRK6MAPTMEN1KMT2A | |
| SCHEMBL6451251 | 0.87 | NPC1 (0.40) | HPGDMAPTMEN1KMT2AALOX15 | |
| SCHEMBL6451336 | 0.86 | IDO1 (0.43) | HPGDMAPTMEN1KMT2AALOX15 | |
| SCHEMBL6453795 | 0.86 | GRK6 (0.42) | HPGDGRK6MAPTMEN1KMT2A | |
| SCHEMBL6452660 | 0.86 | GRK6 (0.45) | HPGDGRK6MAPTMEN1KMT2A | |
| SCHEMBL6450106 | 0.83 | ADORA2A (0.53) | HPGDMEN1KMT2AALOX15ALDH1A1 | |
| SCHEMBL6454836 | 0.82 | GRK6 (0.48) | GRK6MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6449821 | 0.80 | MAPT (0.44) | GRK6MAPTMEN1KMT2AALOX15 | |
| SCHEMBL6451280 | 0.78 | GRK6 (0.48) | HPGDGRK6MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | HPGD 258/4885GRK6 2654/4885MAPT 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.